Chemo-surveillance: a novel concept of the natural defence mechanism against cancer.
Synthetic Antineoplaston A10, 3-phenylacetylamino-2,6-piperidinedione, has been shown to produce promising clinical results, similar to those obtained with antineoplastons derived from urine. Antineoplaston A10 is capable of reducing the excessive excretion of peptides often associated with cancer patients, thereby boosting endogenous levels of antineoplaston. Its therapeutic effect is partially attributable to endogenous antineoplastons, the level of which Antineoplaston A10 can help to raise. A patient must have a certain reserve of endogenous antineoplastons in order to benefit from therapy with Antineoplaston A10. The critical plasma peptide level seems to be above 30 nmoles/ml. Patients who responded favourably to the treatment with Antineoplaston A10 invariably showed an increase of plasma peptide levels and a decrease of urinary excretion of peptides. These results suggest that the body, under normal circumstances, is protected by antineoplastons against cancer. This chemical mechanism of protection is hereby termed chemo-surveillance.
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000652:urine; D044482:Benzeneacetamides; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000517:prevention & control / Q000652:urine*; D010455:Peptides / Q000652:urine*; D010880:Piperidines / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D010881:Piperidones
D000970:Antineoplastic Agents; D044482:Benzeneacetamides; D010455:Peptides; D010880:Piperidines; D010881:Piperidones; C052091:antineoplaston A10